Curium partners with Institut Laue–Langevin to enhance Lutetium-177 supply, benefiting over 100,000 cancer patients in five years.
first doses of PYLCLARI in France for prostate cancer patients
PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...
PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered. PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL), is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:
patient enrollment in clinical trial
Exciting news from Curium! Starting April 5, 2024, our Ioflupane I 123 Injection will be delivered Monday through Friday.
Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.
PARIS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA...
PARIS, July 28, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing authorization for PYLCLARI¢ (INN: Piflufolastat...